What potential risks of SBRT do you counsel patients on when treating early stage lung cancer with an underlying chronic lung infection?  

In a patient with a cavitated lesion with underlying chronic infection (identified as cocci) and SqCC, are there additional risks to SBRT? Should special precautions be taken?



Answer from: Radiation Oncologist at Academic Institution